EXPRESSION OF MATRIX METALLOPROTEASES IN PSORIASIS AND ATHEROSCLEROSIS


Cite item

Full Text

Abstract

Psoriatic and atherosclerotic plaques were analyzed by the real time polymerase chain reaction. The expression of matrix metalloprotease genes (MMP-2 and MMP-9) was changed in psoriatic skin and in atherosclerotic vessels in comparison with intact specimens. Individual analysis for each patient showed that the level of MMP-2 gene expression in psoriatic skin was lower in comparison with the control in the majority of patients, while its level in atherosclerotic plaques was higher than normally. The probable key role of MMP-9 gene in the pathogenesis of psoriasis and atherosclerosis is hypothesized.

About the authors

M. E Sautin

ФГБУН Институт общей генетики им. Н.И. Вавилова РАН

аспирант

A. G Soboleva

ФГБУН Институт общей генетики им. Н.И. Вавилова РАН

канд. биол. наук

A. D Zolotarenko

ФГБУН Институт общей генетики им. Н.И. Вавилова РАН

аспирант

E. S Piruzyan

ФГБУН Институт общей генетики им. Н.И. Вавилова РАН

д-р биол. наук, проф.

I. M Korsunskaya

ФГБУН Центр теоретических проблем физико-химической фармакологии РАН; ГБОУ ВПО Первый МГМУ им. И.М. Сеченова Минздрава России

д-р мед. наук, проф.

P. Yu Orekhov

ФГБУ Федеральный научно-клинический центр специализированных видов медицинской помощи и медицинских технологий ФМБА России

канд. мед. наук

A. V Chupin

ФГБУ Федеральный научно-клинический центр специализированных видов медицинской помощи и медицинских технологий ФМБА России

д-р мед. наук, проф.

S. A Bruskin

ФГБУН Институт общей генетики им. Н.И. Вавилова РАН

канд. биол. наук

V. V Sobolev

ФГБУН Институт общей генетики им. Н.И. Вавилова РАН

Email: sobolew_vl@mail.ru
канд. биол. наук

References

  1. Parks W.C., Wilson C.L., Lopes-Boado Y.S. Matrix metalloproteinases modulators of inflammation and innate immunity. Nat. Rev. Immunol. 2004; 4(8): 617—29.
  2. Hijova E. Matrix metalloproteinases: their biological function and clinical implications. Bratisl. Lek. Listy. 2005; 106(3): 127—32.
  3. Elkington P.T., O’Kane C.M., Friedland J.S. The paradox of matrix metalloproteinases in infectious disease. Clin. Exp. Immunol. 2005; 142(1): 12—20.
  4. Manicone A.M., McGuire K. Matrix metalloproteinases as modulators of inflammation. Semin. Cell Dev. Biol. 2008; 19(1): 34—41.
  5. Van Den Steen P.E., Wuyts A., Husson S.J., ProostP., Van Damme J., Opdenakker G. Gelatinase B/MMP-9 and neutrophil collagenase/ MmP-8 process the chemokines human GCP-2/CXCL6, ENA-78/ CXCL5 and mouse GCP-2/LIX and modulate their physiological activities. Eur. J. Biochem. 2003; 270(18): 3739—49.
  6. Ichikawa Y., Ishikawa T., Momiyama N., Kamiyama M., Sakurada H., Matsuyama R., et al. Matrilysin (MMP-7) degrades VE-cadherin and accelerates accumulation of beta-catenin in the nucleus of human umbilical vein endothelial cells. Oncol. Rep. 2006; 15(2): 311—5.
  7. Meijer M.J., Mieremet-Ooms M.A., van der Zon A.M., van Duijn W., van Hogezand R.A., Sier C.F., et al. Increased mucosal matrix metalloproteinase-1, -2, -3 and -9 activity in patients with inflammatory bowel disease and the relation with Crohn’s disease phenotype. Dig. Liver Dis. 2007; 39(8): 733—9.
  8. Stahle-Bäckdahl M., Sandstedt B., Bruce K., Lindahl A., Jiménez M.G., Vega J.A., López-Otin C. Collagenase-3 (MMP-13) is expressed during human fetal ossification and re-expressed in postnatal bone remodeling and in rheumatoid arthritis. Lab. Invest. 1997; 76(5): 717—28.
  9. Newby A.C. Metalloproteinase expression in monocytes and macrophages and its relationships to atherosclerotic plaque instability. Arterioscler. Thromb. Vasc. Biol. 2008; 28(12): 2108—14.
  10. Rodriguez J.A., Orbe J., Paramo J.A. Metalloproteases, vascular remodeling, and atherothrombotic syndromes. Rev. Esp. Cardiol. 2007; 60(9): 959—67.
  11. Raffetto J.D., Khalil R.A. Matrix metalloproteinases in venous tissue remodeling and varicose vein formation. Curr. Vasc. Pharmacol. 2008; 6(3): 158—72.
  12. Vasku V., Bienertova Vasku J., Slonková V., Kanková K., Vasku A. Matrix metalloproteinase-2 promoter variability in psoriasis. Arch. Dermatol. Res. 2009; 301(6): 467—73.
  13. Lee S.E., Lew W. The increased expression of matrix metalloproteinase-9 messenger RNA in the non-lesional skin of patients with large plaque psoriasis vulgaris. Ann. Dermatol. 2009; 21(1): 27—34.
  14. Flisiak I., Zaniewski P., Chodynicka B. Plasma TGF-beta1, TIMP-1, MMP-1 and IL-18 as a combined biomarker of psoriasis activity. Biomarkers. 2008; 13(5): 549—56.
  15. Feliciani C., Vitullo P., D’orazi G., Palmirotta R., Amerio P., Pour S.M., et al. The 72-kDa and the 92-kDa gelatinases, but not their inhibitors TIMP-1 and TIMP-2, are expressed in early psoriatic lesions. Exp. Dermatol. 1997; 6(6): 321—7.
  16. Livak K.J., Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001; 25(4): 402—8.
  17. Fanjul-Fernández M., Folgueras A.R., Cabrera S., López-Otln C. Matrix metalloproteinases: evolution, gene regulation and functional analysis in mouse models. Biochim. Biophys. Acta. 2010; 1803(1): 3—19.
  18. Fleischmajer R., Kuroda K., Hazan R., Gordon R.E., Lebwohl M.G., Sapadin A.N., et al. Basement membrane alterations in psoriasis are accompanied by epidermal overexpression of MMP-2 and its inhibitor TIMP-2. J. Invest. Dermatol. 2000; 115(5): 771—7.
  19. Пирузян Э.С., Соболев В.В., Абдеев Р.М., Золотаренко А.Д., Николаев А.А., Саркисова М.К. и др. Изучение молекулярных механизмов патогенеза иммуноопосредованных воспалительных заболеваний на примере псориаза. Acta Natura. 2009; 3: 139—50.
  20. Соболев В.В., Золотаренко А.Д., Соболева А.Г., Елкин А.М., Ильина С.А., Серов Д.Н. и др. Влияние экспрессии гена FOSL1 транскрипционного фактора АР-1 на псориатический процесс. Бюллетень экспериментальной биологии и медицины. 2010; 150(11): 564—7.
  21. Соболев В.В., Золотаренко А.Д., Соболева А.Г., Саутин М.Е., Ильина С.А., Саркисова М.К. и др. Экспрессия гена FOSL1 при псориазе и атеросклерозе. Генетика. 2010; 46(1): 104—10.
  22. Gonsky R., Deem R., Hughes C., Targan S.R. Activation of the CD2 pathway in lamina propria T cells up-regulates functionally active AP-1 binding to the IL-2 promoter, resulting in messenger RNA transcription and IL-2 secretion. J. Immunol. 1998; 160(10): 4914—22.
  23. Chandrasekar B., Mummidi S., Mahimainathan L., Patel D.N., Bailey S.R., Imam S.Z., et al. Interleukin-18-induced human coronary artery smooth muscle cell migration is dependent on NF-kappaB- and AP-1-mediated matrix metalloproteinase-9 expression and is inhibited by atorvastatin. J. Biol. Chem. 2006; 281(22): 15099—109.

Copyright (c) 2013 Eco-Vector


 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies